Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as first line regimen in people with HIV: a retrospective observational study DOI Creative Commons
Andrea Giacomelli, Maria Vittoria Cossu, Davide Moschese

et al.

IJID Regions, Journal Year: 2025, Volume and Issue: 15, P. 100622 - 100622

Published: March 6, 2025

To assess the effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in patients newly diagnosed with HIV (PWH) a non-experimental setting. We conducted single-center, retrospective observational study that included all PWH treated TAF/FTC/BIC at our institution. Virological failure was defined as two consecutive HIV-RNA values >50 cp/ml after 48 weeks treatment. Reasons for interruption were also collected. The durability estimated using Kaplan-Meier curves. A total 236 started TAF/FTC/BIC, median follow-up time 13 months (interquartile range [IQR] 4-27 months). Most cisgender men (178/236, 75.4%) age diagnosis 37 years (IQR 29-48) cluster differentiation 4 cell counts 302 cells/mm³ 117-467). One protocol-defined virological observed, without development drug resistance, resulting an incidence 3.1 per 1000 person-years (95% confidence interval [CI] 0.8-17.3). Six (2.5%) discontinued because toxicity. durabilities 12 24 84.8% CI 78.6-89.3%) 75.5% 67.6-82.6%), respectively. In cohort low occurrence discontinuation related to toxicities underscores tolerability regimen.

Language: Английский

Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as first line regimen in people with HIV: a retrospective observational study DOI Creative Commons
Andrea Giacomelli, Maria Vittoria Cossu, Davide Moschese

et al.

IJID Regions, Journal Year: 2025, Volume and Issue: 15, P. 100622 - 100622

Published: March 6, 2025

To assess the effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in patients newly diagnosed with HIV (PWH) a non-experimental setting. We conducted single-center, retrospective observational study that included all PWH treated TAF/FTC/BIC at our institution. Virological failure was defined as two consecutive HIV-RNA values >50 cp/ml after 48 weeks treatment. Reasons for interruption were also collected. The durability estimated using Kaplan-Meier curves. A total 236 started TAF/FTC/BIC, median follow-up time 13 months (interquartile range [IQR] 4-27 months). Most cisgender men (178/236, 75.4%) age diagnosis 37 years (IQR 29-48) cluster differentiation 4 cell counts 302 cells/mm³ 117-467). One protocol-defined virological observed, without development drug resistance, resulting an incidence 3.1 per 1000 person-years (95% confidence interval [CI] 0.8-17.3). Six (2.5%) discontinued because toxicity. durabilities 12 24 84.8% CI 78.6-89.3%) 75.5% 67.6-82.6%), respectively. In cohort low occurrence discontinuation related to toxicities underscores tolerability regimen.

Language: Английский

Citations

0